OBJECTIVES: Despite impressive results in diagnosis and treatment of non-small-cell lung cancer (NSCLC), more than 30% of patients with Stage I NSCLC die within 5 years after surgical treatment. Identification of prognostic factors to select patients with a poor prognosis and development of tailored treatment strategies are then advisable. The aim of our study was to design a model able to define prognosis in patients with Stage I NSCLC, submitted to surgery with curative intent.
Exploring Stage I non-small-cell lung cancer: development of a prognostic model predicting 5- 
INTRODUCTION
Lung cancer remains the prominent cause of cancer deaths worldwide in both men and women. Pulmonary resection offers the only potentially curative treatment for patients with localized non-small-cell lung cancer (NSCLC). Despite impressive results in diagnosis and treatment attained so far, more than 30% of patients with Stage I NSCLC die within 5 years after surgical treatment [1] . Among stage I NSCLC, the tumours' biological behaviour could be very heterogeneous: after surgical resection, some patients experience a long-term survival, while others present with an early disease progression. Moreover, survival rates reported by several studies range between 55 and 85%, adding further variability. In the last decades, many different prognostic factors have been proposed, with variable levels of evidence [2] .
This brings to light the necessity of delineating predictors of prognosis, to propose risk-related individual treatment to patients. Furthermore, identification of prognostic factors is helpful to compare patient cohorts among different clinical studies.
Our purpose was to design a prognostic score, using clinical and pathological criteria easily available in daily practice, to define prognosis in patients with Stage I NSCLC, submitted to surgery with curative intent.
PATIENTS AND METHODS
This is a retrospective cohort study on patients submitted to surgery for Stage IA and IB NSCLC. Retrospective data were collected from surgical registries of the two participating centres: San Giovanni Battista Hospital (Turin, Italy) and San Luigi Gonzaga Hospital (Orbassano, Italy). Exclusion criteria included any preoperative treatment regimen (e.g. chemotherapy, radiotherapy) and any neuroendocrine histology subtype (e.g. carcinoid, large-cell neuroendocrine carcinoma). Surgical procedures were usually performed through a muscle-sparing axillary or postero-lateral thoracotomy.
Data variables and outcomes
To increase consistency and reproducibility of the results, clinical variables collected from the participating Institutions matched the European Society of Thoracic Surgeons (ESTS) endorsed Database. The final data set for the analyses included the following data: age, sex [3] , smoking habit, cardiac morbidities (coronary artery disease, previous cardiac surgery, current treatment for hypertension, arrhythmia or cardiac failure), other comorbidities (insulin-dependent diabetes, serum creatinine >2 mg/dl, previous cerebro-vascular accident), previous malignancies, Eastern Cooperative Oncology Group performance status (ECOG-PS), clinical N stage, maximum standardized uptake value (SUV max ), forced expiratory volume in 1 s (FEV 1 ), carbon monoxide lung diffusion capacity (DLCO), surgical resection type, lymph node status assessment, histology, histological grading, microscopic vascular invasion, pathological TNM stage and survival data.
According to the ESTS guidelines [4] , we described intraoperative lymph node assessment as follows:
• Lymph node sampling (LS): removal of one or more lymph nodes, guided by preoperative or intraoperative findings.
• Systematic nodal dissection (SND): all mediastinal tissue containing lymph nodes is dissected and removed systematically within anatomical landmarks. The hilar and the intrapulmonary lymph nodes are dissected as well. At least three mediastinal nodes are excised as a minimum requirement.
Surgery was defined as radical (R0) when a complete tumour resection was accomplished, and incomplete in case of microscopically (R1) or macroscopically (R2) residual disease.
Histological grading was categorized into well-(G1), moderately-(G2) and poorly differentiated (G3) carcinoma according to degree of architecture and cytological atypia.
Statistical analysis
Categorical data are presented as number (percentage, %), continuous data as median [interquartile range (IQR)]. In order to identify the optimal cut-off, continuous variables were dichotomized using classification and regression tree analysis (cart command in STATA). Missing data in evaluated predictors were multiple-imputed and combined estimates were obtained from 10 imputed data sets.
Primary outcome was overall survival (OS). Survival was calculated from the date of intervention to the date of death by any cause; patients alive were censored on the date of last follow-up. Survival curves were estimated using the Kaplan-Meier method and significant differences in survival between groups were investigated with Cox univariate regression models with shared frailty (accounting for the within-centre correlation). The results of the univariate analysis are not reported in the text, in order not to lengthen the paper. Possible predictors of survival were investigated using Cox multivariate proportional hazards regression; the backward selection method was assessed to estimate the predictors and to select the most relevant ones. Predictors of OS associated with P ≤ 0.2 on multivariate analysis were included in the final model and discrimination ability was estimated with the C-statistic. A calibration plot describing the relationship between the predicted versus observed 5-year survival was constructed, to provide a graphical measure of calibration of the final model. Two hundred bootstrap samples were drawn from the original data set with replacement and, within each bootstrap sample, the entire modelling process described above, including the backward stepwise selection of predictors, was repeated. The optimismcorrected C-statistic was estimated according to bootstrap process results.
The additive risk score was designed from coefficients of the significant predictor estimates: a value of 1 point was assigned to the smallest coefficient and the other values were assigned by reason of proportional weighing. In addition, cases were grouped in four classes of incremental risk, according to their total score. χ 2 test and Fisher's exact test, when appropriate, were used to evaluate the differences in variables frequencies in the individuated prognostic group. The additive prognostic value of score and the cut-off points evaluated in imputed data sets were applied to initial patient population: Kaplan-Meier methods and Cox regression were carried out to compare survival variances in the four risk groups.
All statistical analyses were performed using STATA (version 12.1) and R (version 3.1).
RESULTS
Eight hundred and eighty-four consecutive cases were included in the final analysis (Fig. 1) . The demographics and clinical characteristics of the population and derivate groups are illustrated in Table 1 , and surgical and pathological features in Table 2 . Most patients were male (610, 72%); median age at surgery was 67 years (IQR 62-73). Smoking habit was reported in 727 (86%) cases and 563 patients (77%) presented with at least one comorbidity at the time of intervention. Two hundred and eighty-eight (34%) patients had a previous history of malignancy. Adenocarcinoma was the commonest histological type (551, 65%), followed by squamous cell carcinoma (247, 29%), bronchioloalveolar carcinoma (25, 3%) and large-cell carcinoma (25, 3%). Pathological TNM stages were equally distributed between stage IA (439, 52%-T1a 249, 29%; T1b 190, 23%) and IB (409, 48%).
Predictors and outcome
The mean follow-up time was 48 months and, at the end of the study period, 209 patients died (25%). In the analysed population, the overall 5-year survival rate was 74% (95% confidence interval 0.71-0.77, Fig. 2 ). In the final Cox regression model, age (>75 years), male sex, presence of cardiac comorbidities, DLCO (<50% predicted), SUV max (≥9), LS, presence of microscopic vascular invasion, pTNM stage, histological grading (as a linear increment from G1 to G3) were independent predictors of worse survival (Table 3 , Supplementary Figs S1-S10). The final model showed a fair discrimination ability (C-statistic = 0.69); the calibration plot of the model indicated a good agreement between observed and predicted 5-year survival on the whole range of probabilities (Fig. 3) and bootstrapping showed consistency of the results (C-statistic = 0.68, Table 3 ). As explained above, regression coefficients-adjusted and rounded-were converted into the prognostic score points. The resultant additive risk score identifies four groups, which present low-, intermediate-, high-or very high risks (P < 0.0001, Table 4 ). Five-year survival significantly decreases from the low-risk to the very high-risk class (P < 0.0001, Fig. 4 
DISCUSSION
The present cohort study represents a first attempt to create a clinical and pathological prognostic score for surgically resected Stage I NSCLC.
The results of our study suggest that (i) age, male sex, presence of cardiac comorbidities, DLCO, SUV max , lymph nodal sampling, presence of microscopic vascular invasion, pTNM stage and histological grading are independent predictors of survival; (ii) in a research setting, the proposed additive risk score is helpful to collapse several predictors while decreasing the degrees of freedom and (iii), for clinical purpose, it could be suitable to improve prognostic stratification of patients' risk.
Correct prediction for patients with NSCLC is clinically essential but complex to define. The TNM staging system and performance status are the only validated prognostic indicators for survival [2] . In early-stage NSCLC, these predictors are associated with a low sensitivity: 5-year survival rates reported in the literature fluctuate from 55 to 85% [5, 6] . A more refined estimate of outcome in early-stage NSCLC is strongly needed to design tailored treatment and to improve prognosis. Moreover, a precise identification of prognostic groups is valuable to evaluate treatment options and to compare cohorts in research settings. In addition to detailed molecular In the present series, the 5-year OS rate is 74%; this value is higher than that in some multi-institutional reports [5, 6] . This is probably due to homogeneity and accuracy of the pathological staging, quality of the data set and uniformity in treatment strategies. In our study age, male sex, presence of cardiac comorbidities, DLCO, SUV max , LS, presence of microscopic vascular invasion, pTNM stage and histological grading resulted to be independent indicators of worse prognosis and were therefore incorporated in the prognostic score. With regard to patients' age, most of the studies described a similar trend in the survival benefit of surgical resection between younger and older patients [7, 8] . Some series reported a worse OS in advanced age [5] . Nevertheless, NSCLC is an aggressive and fatal disease in all age clusters, and it is established that in unresected patients, mortality is more often due to lung cancer than to the age factor [7] . In our cohort, we observed a significant worse survival only in patients older than 75 years at intervention. Hence, in earlystage NSCLC, surgical resection, when feasible, seems to provide a satisfactory survival benefits, even in old patients.
The WHO reported a growing incidence of NSCLC in women [9] , but lower mortality rates than in men [10] . In addition, The Lung Cancer Staging Project, conducted by the International Association for the Study of Lung Cancer (IASLC) in 2009, described that men have a 30% higher risk of death from NSCLC, compared with women [11] : this correlation was confirmed by several authors, also in early-stage NSCLC [5, 8] . Molecular differences between NSCLC in men and women, like DNA repair capacity [12] and rates of driver mutations (e.g., epidermal growth factor receptor and K-RAS mutations [13] ), may contribute to variances in NSCLC clinical behaviour between the sexes. In our series, female patients also showed better survival than male: this result confirms the need to focus on sex-driven differences in lung cancer research in future. Impaired DLCO has been described as an indicator of worse overall and cause-specific long-term survival [14] [15] [16] . Some authors recognize a preoperative DLCO of 40% predicted as the cut-off value for an increased risk of death [14] , while recently others confirmed a clear effect on mortality risk with DLCO lower than 70-80% predicted [15, 16] . In our study, we identified an optimal threshold at 50% predicted to define a subgroup of patients with poorer survival.
Positron emission tomography (PET) with radiolabelled [18F] fluorodeoxy-D-glucose is widely used for the preoperative staging and for screening for distant metastases. The prognostic significance of maximum standardized uptake value (SUV max ), which quantifies the glucose uptake of the tumour, was described in resected early-stage NSCLC [17] . In our series, we observed an asymptotic pattern of the 5-year mortality rate, when SUV max measured ≥9 (Supplementary Fig. S6 ). Using the proposed dichotomization, SUV max was found to have an impact on survival and was therefore incorporated in the additive score.
In the current NSCLC TNM staging system, the anatomical extent of lymph nodal metastases was used to define the N category. Even if tumours may appear localized on CT or PET scans, lymph nodes could be involved by metastatic spreads. Therefore, lymph node assessment is fundamental for an accurate lung cancer staging [4] . Nevertheless, the extent of lymphadenectomy and the impact of N2-node removal on survival in early-stage NSCLC remain controversial. Several series evaluated the supposed superiority of SND over LS with conflicting results [18, 19] . In addition, SND can be performed without increase in perioperative or long-term morbidity [20] . Our results showed a dramatic improvement in survival when SND was performed (Supplementary Fig. S8 ). Potential explanations of this result could be: the possible therapeutic excision of minimal disease in mediastinal lymph nodes or a stage migration phenomenon, resulting from a higher staging accuracy with increased number of lymph nodes resected. Future studies are needed to clarify this issue.
Microscopic vascular invasion is one of the prominent steps of metastatic spreading and its significance was confirmed in other solid tumours (breast and colorectal cancer) [21] . Our analysis confirms the presence of vascular invasion as an independent predictor of poor prognosis. However, there is no definite agreement on the value of its prognostic role worldwide: the majority of authors verified the correlation between vascular invasion and survival [21] , while others did not [22] . As a consequence, our findings deserve to be confirmed in future studies.
Some evidence of the influence of NSCLC histological grading on survival was present in the literature [23] . Our results showed a nice stratification according to histological grading ( Supplementary Fig. S11 ). On the other hand, we did not find any significant impact of tumour histology on survival in multivariate analysis. In the future, new addenda to score components could emerge from new advances in adenocarcinoma subtype research [24] . This paper presents some potential criticisms. Our cohort is retrospectively collected and pulmonary resections were achieved through a muscle-sparing axillary or postero-lateral thoracotomy. Other types of surgical accesses (e.g. video-assisted thoracic surgery, robotic-assisted thoracic surgery) were not performed; therefore, the value of the proposed prognostic score needs to be confirmed in patients submitted to minimally invasive resections. Moreover, even if the cohort size is relatively large, further studies based on a larger patient sample will be required to confirm the obtained results and to provide an external validation in a multicentre setting.
In conclusion, we designed an effective prognostic model based on clinical, pathological and surgical covariates. Further investigation might be necessary to define if higher risk groups may benefit from a strict follow-up schedule or adjuvant treatment options.
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